Newly renamed CSI Dry Eye Innovations has kicked off 2026 with an updated corporate brand and a newly-issued patent for its flagship dry eye disease (DED)-focused technology.
First, a look at this company.
Founded in 2019, the Canadian-based software company is best known as the developer and provider of its flagship product: CSI Dry Eye Software.
Its origins: This technology was designed by dry eye specialists—Ahmed Al-Ghoul, MD, to be specific— “who were fed up with the inconsistencies surrounding the diagnosis, care, and treatment of dry eyes,” as the company put it.
- Referred to as the culmination of “years of research and development,” the software is reportedly the “first machine-learning, cloud-based software of its kind to enable doctors and patients to see the whole picture behind dry eyes.”
Before we talk tech, explain this rebrand.
To be clear: The company has changed its name from CSI Dry Eye Software to CSI Dry Eye Innovations.
- Why: Essentially, CSI noted that this creates a “clearer communication of CSI’s role in dry eye care” as well as a clearer distinction between the company itself, its flagship software, and any future products developed under its new parent brand name moving forward.
And along with its "refreshed visual identity,” the company will reportedly launch a new website in the near future.
Speaking of developments … doesn’t the company also have a new CEO?
Yes! CSI announced Lisa Rickards as its new CEO in October 2025.
She succeeded Ken Barbet, who served at the helm since April 2025.
Noted. Now, let’s get a rundown on CSI’s software.
CSI Dry Eye Software is an artificial intelligence (AI)-based, service-as-a-service (SaaS) clinical platform designed to support DED diagnosis and management.
What it does: Analyzes the results of various tests and questionnaires—taken by both eyecare professionals (ECPs) and patients—to assist ECPs in identifying potential causes and treatments for their patients.
Where does the AI component come in?
Through evidence-based algorithms and machine learning processes, which are utilized to eliminate biases in both the diagnosis and treatment processes.
Per CSI: “Our system allows for evidence-based medicine to be applied hand-in-hand with real-life analysis of outcomes, so patients achieve the result they are looking for faster and more effectively.”
And how exactly does it work?
The platform’s approach targets the root causes of dry eye symptoms by conducting a “deep-dive” evaluation of all potential causes / associations of the disease.
The intent: To establish “a baseline of a patient’s dry eye status” and enable ongoing monitoring of their response to treatments (procured from the software’s in-house database).
- See here for a step-by-step look at the entire process.
So about that newly-issued patent …
Ah yes. CSI noted that the patent “protects the core clinical reasoning framework” behind its software.
That framework, the company stated, involves:
- Analyzing multiple dry eye indicators
- Determining subtype and severity
- Generating explainable, ranked treatment pathways to support clinical decision-making
CSI emphasized that the technology neither diagnoses autonomously nor replaces clinician judgment—rather: “it provides standardized, evidence-based structure while preserving full clinical authority.”
How long is it good for?
While Glance was unable to confirm CSI’s patent number, software such as the company’s would fall under the classification of a design patent.
Meaning: In the U.S., design patents generally last 15 years from the date they were granted.